University of Ioannina
Clonal heterogeneity and biomarkers in colorectal cancer with liver metastasis
Abstract
dc:descriptionPurpose: Colorectal cancer (CRC) ranks as third most common cancer type across both sexes and the second leading cause of cancer-related mortality worldwide. However, despite the standardization of multi-modal treatmentm the mechanisms underlying high drug resistance and relapse rates after complete tumor resection and adjuvant and/or neo-adjuvant therapy in patients with CRC and liver metastasis (LM) remain poorly understood. Based on recent data on intratumor heterogeneity (ITH) and circulating cell-free DNA (cfDNA) variability, we have developed and designed a prospective study to evaluate potential translational implications of comprehensive intra-patient heterogeneity, comprising primary and metastatic ITH coupled with plasma DNA mutational landscapes in each individual patient.Patients and methods: Our prospective study enrolled 18 patients with resectable CRC-LM and a total of 122 multi-regional tumor and perioperative liquid biopsies were analyzed via next-generation sequencing (NGS) of a custom 77-gene panel. The primary aims of the present study include the exploration of the extent of ITH in matched primary and metastatic tumors, the detection of perioperative cfDNA mutations, as well as the potential clinical utility of comprehensive intra-patient actionable mutational landscapes.Results: Overall, ITH of the primary and metastatic lesions was detected in 53% and 56% of patients respectively. Additionally, genetic differences between matched primary CRC and LM was identified in 53% of patients in our cohort and 35% of LMs harbored de novo mutations. Analysis of cfDNA uncovered mutations in 56% of patients, while 25% of patients harbored de novo cfDNA mutations, not detected in the multi-regional tumor NGS analysis. Among 17 patients with detectable mutations, all harbored actionable alterations either approved or under evaluation in clinical trials or pre-clinical studies, at an average of 3.2 per patient.Conclusions: Our proof-of-concept prospective study provides initial evidence of comprehensive intra-patient genetic heterogeneity with translational implications to overcome drug resistance and relapse, thus warranting the conduction of and precision clinical trials.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kyrochristos, Ioannis
- Κυροχρήστος, Ιωάννης
Subjects
dc:subject × 20- Ενδο-ογκική ετερογένεια
- Κυκλοφορούσα ετερογένεια
- Αλληλούχιση επόμενης γενιάς
- Βιοδείκτες
- Θεραπευτικοί στόχοι
- Intratumor heterogeneity
- Circulating heterogeneity
- Next-generation sequencing
- Biomarkers
- Drug targets
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ογκολογία
- Βασική Ιατρική
- Γενετική ανθρώπου
- Clinical Medicine
- Medical and Health Sciences
- Oncology
- Basic Medicine
- Human genetics
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/51560